ABOUT AST
Since 1965, AST has been delivering innovative solutions – many of which were industry firsts and have since become industry standards. AST has always understood that our customers serve demanding and oftentimes unpredictable markets. We also understand that “flexibility is the antidote to uncertainty,” and as your partner, AST consistently seeks to deliver innovative solutions that are robust, yet flexible. AST is a technology leader specializing in advanced aseptic filling and closing systems. Our focus is to provide innovative and flexible products that satisfy the most challenging product and regulatory requirements for the Pharmaceutical and Biotechnology industries. AST’s spectrum of products includes semi-automated to completely automated and integrated cGMP manufacturing systems for processing vials, syringes and cartridges. To discover more about our products please select a product category.
CONTACT INFORMATION
AST
4110 South Washington Street
Tacoma, WA 98409
UNITED STATES
Phone: 253-475-0200
Contact: Brittany Cooksey
FEATURED ARTICLES
-
Learn about the development process behind a new, state-of-the-art fill-finish isolator that's addressing issues in isolator manufacturing and servicing, as well as meeting the needs of the liquid pharmaceutical market.
-
CURIS System, an innovator in advanced decontamination technology, and AST, a leader in aseptic fill-finish processing technology, today announced a groundbreaking partnership. This collaboration marks a significant step forward in the pharmaceutical manufacturing industry, as the two companies combine technology to revolutionize the biodecontamination of aseptic fill-finish isolators using CURIS's disruptive vapor decontamination technology.
-
AST has over 50 years of experience designing, manufacturing, and servicing innovative, high quality and highly automated processing equipment. Beginning in 2006, AST leveraged our experience and close customer relationships to revolutionize the aseptic fill/finish industry with the launch of the ASEPTiCell® development.
-
The path to a successful life science startup is exciting, difficult, and unpredictable. Recent years have seen a volatile pattern emerge of challenge, change and innovation within the life sciences.
-
Aseptic fill-finish professionals are continually looking to augment their approach to a market that continues to grow and reflect innovations happening around sterile parenteral treatments.
-
Establishing early and clear tech transfer strategies is a key component of a holistic approach to drug development. Learn about the role that capable fill-finish solutions play in this process.
-
One of the most intriguing, high-stakes aspects of R&D is the realm of biosimilars. Explore the challenges of biosimilar production as well as aseptic processing considerations for biosimilars.
-
Germfree Laboratories, a global leader in isolator technology for aseptic processing and containment in the pharmaceutical sector, and AST, a pioneer in aseptic fill-finish processing technology, are thrilled to announce a revolutionary partnership. This landmark collaboration is set to redefine industry standards, launching a new era of innovation and efficiency.
-
Here, we share one of the best ways to ensure sterility in aseptic compounding operations and how 503A and 503B pharmacies can achieve the adaptability they need to scale their operation.
-
Explore best aseptic practices for cell and gene therapy production that will be foundational to the ongoing development of these therapies as well as their successful manufacturing operations.
-
The rapid rise of highly targeted cell and gene treatments requiring small batch production necessitates a new path forward for biologics manufacturing and directly impacts the CMO/CDMO landscape.
-
When selecting an aseptic fill/finish machine, the choice to use a gloved or gloveless isolator will arise. To help with that decision, here are a few attributes to consider.
-
With regulatory requirements and GMP recommendations trending towards less human interaction and more robotic automation, robotics is the way of the future for the ATMP industry.
-
It's essential to understand how scaling up is affecting your aseptic filling operations. Here are four topics to consider to help ensure your drug product will be taken care of and ready for production.
-
Cell and gene therapies continue to gain significant traction in the biopharmaceutical world. While this technology continues to grow, challenges will inevitably follow. Explore considerations for aseptic fill/finish challenges.
-
The reason for the existence of the pharmaceutical world is simple – People need medicine. How you get that medicine to the patient is the big question. While many different facets of medicine were brought to light by the COVID-19 pandemic, possibly none were viewed as more important than the need for increased urgency when dealing with medicine that can save the life of a patient in need.
-
Small-scale aseptic filling presents a unique set of challenges. Learn what to look for when evaluating small-scale aseptic filling technology.
-
Automated Systems of Tacoma, LLC (AST), a leading provider of flexible aseptic filling systems, announces Josh Russell has rejoined AST as the Vice President of Sales & Marketing. Josh lives in Philadelphia, PA region and rejoins the AST team after three years at AES Clean Technologies as VP of Sales & Marketing. Previously, Josh worked at AST over a fifteen-year span holding several positions of responsibility including leading the development of AST’s fill-finish systems product line, and later as Vice President of Business Development.
-
The current and future wave of pharmaceutical and biotechnology products is making historical aseptic filling machine manufacturing methodologies inadequate and antiquated. Traditional production processes used for high-volume drug products are stressed to efficiently meet the production requirements of targeted medicines that dominate today’s clinical pipelines.
-
AST, a leading provider of flexible aseptic filling systems, announces they are now offering delivery of their most popular isolated equipment within 6 months of purchase. This is a dramatic improvement over typical industry delivery times, which are often up to 24 months. AST knows that time to market is critical in delivering drug products to sick patients, and quick delivery demonstrates their commitment to reducing the time it takes to provide critical treatments.
AST VIDEOS
-
Watch as Josh Russell, VP of Sales and Marketing, AST, demonstrates the GENiSYS® C aseptic filling system, ideal for use in small-scale filling applications.
-
Josh Russell, VP of Sales & Marketing, describes the AST Quick Delivery program, which makes certain isolated fill finish equipment available within six months of purchase.
-
Join Keith Dodson of Automated Systems to discover small batch aseptic solutions for cell therapy, gene therapy, vaccines, R&D, biosimilars and CDMO’s.
-
The AST GENiSYS R provides ultimate flexibility for the aseptic filling of liquid pharmaceuticals. Designed with the specific challenges of small-batch production in mind, the GENiSYS R can be built to meet the needs of your facility today and for years to come. Learn more in our latest video.
-
The 4th generation GENiSYS C is an advanced yet compact solution for automated aseptic processing of liquid pharmaceutical products, with many features typically reserved for large scale filling lines. Learn more in our latest video.
-
ASEPTiCell provides flexible, robotic filling and finishing of vials, syringes and cartridges for small to medium clinical and commercial batches. The modular design allows the ASEPTiCell to be built to your specification without the cost and risk of customization.
-
The GENiSYS® R offers a unique blend of automated capabilities to ensure your sterile products are processed in strict accordance with cGMP requirements. With robotic handling available from bag opening to vial sealing, and integration with barrier technologies, your product is protected from contamination through all stages of processing.
-
GENiSYS® R provides ultimate flexibility for processing ready-to-use vials, syringes and cartridges on a single machine. Highly reliable robotics and recipe driven changeovers allow for complete format changes in as little as 30 minutes. Maximize productivity and return-on-investment with the GENiSYS R.
-
AST’s GENiSYS® Lab semi-automatic systems are ideal for drug product development and cGMP production applications. Each system automates the critical aseptic operations for vial, syringe and cartridge processing to reduce contamination risk and product variability. GENiSYS Lab offers a perfect balance between automated features, size and affordability without compromising quality, safety and ease of use.
-
Is the general opinion about robotics improving? Watch this webinar to learn more about where and how robotics add value and solve problems.
-
This presentation addresses the changing needs for the manufacturing of biologics and the rationale for the use of robotics and automation in aseptic fill and finish processing of these products.